CHAIR
:
SPEAKER
(S):
Irene Norstedt, PhD, Head of Sector Innovative Medicines, Health Research Directorate, European Commission , European Commission -- DG Research
Wendy Sanhai, PhD, Senior Scientific Advisor, Office of the Commissioner , U.S. Food and Drug Administration
Jacky Vonderscher, PhD, Co-Director Critical Path Institute, V.P, Global Head of Molecular Medicine Labs, Hoffmann-La Roche , Critical Path Institute
David Wholley, MA, Director, The Biomarkers Consortium , Foundation for the National Institutes of Health
Description
Public-private partnerships, both U.S. and European, have been created to leverage cutting-edge techniques and technologies to prevent safety and toxicity issues. In this session you will learn about the latest efforts in biomarker identification, in silico modeling and simulation, and new testing methods applied by the Critical Path Institute, Innovative Medicines Institute (IMI), NIH's Biomarker Consortium and the DILI Initiative to drive change in drug development.
Objective1:Stimulate debate on how public and private industries are working toward predicting safety issues.
Objective2: Outline research approaches used to improve drug safety.
Objective3: Promote an understanding and awareness of programs that bring together different stakeholders.